Gilead Sciences (NASDAQ:GILD) Given New $156.00 Price Target at Truist Financial

Gilead Sciences (NASDAQ:GILD) had its target price dropped by equities research analysts at Truist Financial from $157.00 to $156.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Truist Financial’s target price would suggest a potential upside of 20.36% from the company’s current price.

Other research analysts also recently issued reports about the stock. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Gilead Sciences in a report on Monday, June 8th. Leerink Partners cut their price objective on Gilead Sciences from $148.00 to $146.00 in a report on Friday, May 8th. Jefferies Financial Group assumed coverage on Gilead Sciences in a research report on Tuesday, March 10th. They set a “buy” rating and a $180.00 price objective on the stock. HSBC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and increased their target price for the company from $133.00 to $155.00 in a research report on Monday. Finally, Wall Street Zen cut Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Twenty-six investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $159.19.

Gilead Sciences Stock Down 1.3%

GILD stock opened at $129.61 on Tuesday. The stock has a market capitalization of $160.92 billion, a P/E ratio of 17.66 and a beta of 0.32. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89. Gilead Sciences has a 12 month low of $107.75 and a 12 month high of $157.29. The firm has a 50-day moving average price of $129.44 and a 200-day moving average price of $134.64.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.12. The company had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm’s revenue was up 4.4% on a year-over-year basis. During the same period in the previous year, the firm posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities research analysts anticipate that Gilead Sciences will post -0.8 EPS for the current fiscal year.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the sale, the chief financial officer directly owned 171,646 shares in the company, valued at approximately $21,524,408.40. The trade was a 1.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $131.46, for a total value of $1,971,900.00. Following the transaction, the chief executive officer owned 617,567 shares in the company, valued at $81,185,357.82. The trade was a 2.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 83,000 shares of company stock valued at $10,824,500 in the last ninety days. 0.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Gilead Sciences

A number of large investors have recently bought and sold shares of the stock. Norges Bank acquired a new position in shares of Gilead Sciences during the fourth quarter valued at about $2,617,152,000. Boston Partners bought a new stake in Gilead Sciences in the 4th quarter valued at about $517,808,000. Massachusetts Financial Services Co. MA raised its stake in Gilead Sciences by 3,763.8% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock worth $518,368,000 after buying an additional 4,113,999 shares during the period. Bank of America Corp DE boosted its holdings in Gilead Sciences by 15.2% in the fourth quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company’s stock worth $2,837,948,000 after acquiring an additional 3,046,688 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Gilead Sciences by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after acquiring an additional 2,113,692 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.